M. Stoltz
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- Immunology and Allergy top 10%
- Allergic Rhinitis and Sensitization
Papers in
- Surgery 4
- Orthopedic Surgery and Rehabilitation 2
-
- Antibiotics Pharmacokinetics and Efficacy 2
- Co-authors
- Scott J. Weir (2 shared papers)Tanya L. Russell (1 shared paper)David H. Ilson (2 shared papers)P. Maslak (2 shared papers)David P. Kelsen (2 shared papers)William P. Tong (2 shared papers)Eileen M. O’Reilly (2 shared papers)Leonard B. Saltz (2 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)The Journal Of Hand Surgery (1 paper)Clinical Chemistry (1 paper)Arthroplasty Today (1 paper)Blood (1 paper)
- Partner nations
- United StatesGermany
In The Last Decade
M. Stoltz
17 papers receiving 609 citations
Peers
Comparison fields: 5 of 83
- Oncology 198
- Immunology and Allergy 41
- Hematology 58
- Genetics 52
- Health, Toxicology and Mutagenesis 58
Countries citing papers authored by M. Stoltz
This map shows the geographic impact of M. Stoltz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Stoltz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Stoltz more than expected).
Fields of papers citing papers by M. Stoltz
This network shows the impact of papers produced by M. Stoltz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Stoltz. The network helps show where M. Stoltz may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Stoltz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2001 | 151 | |
| 2 | 2002 | 129 | |
| 3 | 1998 | 106 | |
| 4 | 2002 | 58 | |
| 5 | 2008 | 53 | |
| 6 | 1978 | 32 | |
| 7 | 1982 | 23 | |
| 8 | 1997 | 21 | |
| 9 | 2006 | 17 | |
| 10 | Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors. | 2002 | 12 |
| 11 | 2024 | 11 | |
| 12 | 1988 | 10 | |
| 13 | A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. | 2001 | 6 |
| 14 | 2007 | 5 | |
| 15 | 2015 | 2 | |
| 16 | 2012 | 2 | |
| 17 | 2006 | 1 | |
| 18 | 2025 | 0 | |
| 19 | 2024 | 0 |
About M. Stoltz
M. Stoltz is a scholar working on Surgery, Pharmacology, Pediatrics, Perinatology and Child Health, Oncology and Epidemiology, having authored 19 papers that have together received 639 indexed citations. Recurring topics across this work include Pneumocystis jirovecii pneumonia detection and treatment (3 papers), Orthopedic Surgery and Rehabilitation (2 papers), Acute Myeloid Leukemia Research (2 papers), Metabolism and Genetic Disorders (2 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers), HIV/AIDS drug development and treatment (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (198 citations), Immunology and Allergy (41 citations), Hematology (58 citations), Genetics (52 citations) and Health, Toxicology and Mutagenesis (58 citations). M. Stoltz has collaborated with scholars based in United States and Germany. Frequent co-authors include Scott J. Weir, Tanya L. Russell, David H. Ilson, P. Maslak, David P. Kelsen, William P. Tong, Eileen M. O’Reilly, Leonard B. Saltz, Gary K. Schwartz and R. H. McKee. Their work appears in journals such as Journal of Clinical Oncology, The Journal Of Hand Surgery, Clinical Chemistry, Arthroplasty Today and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.